REFERENCES
- Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639.
- Manthey CL, Perera PY, Salkowski CA, Vogel NS. Taxol prvides a second signal for murine macrophage tumori-cidal activity. J Immunol 1994; 152: 825.
- McLaughlin P, Grillo-Lopez AJ, Link BD et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825.
- Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B. Synergistic anti-tumoral effect of paclitaxel (Taxol)+A5101 in a murine model of B16 melanoma: associa-tion with ras-dependent signal-transduction pathways. International Journal of Cancer 2000; 86: 281.
- Mehta S, Blackinton D, Manfredi M, Rajaratnam D, Kouttab N, Wanebo H. Taxol pretreatment of tumor targets amplifies natural killer cell-mediated lysis. Leuk & Lymph 1997; 26: 67.
- Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268.
- Deo YM, Graziano RF, Repp R, van de Winkel JGJ. Clinical significance of IgG Fc receptors and Fcg R-directed immunotherapies. Immunol Today 1997; 18: 127.
- Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM. Cytolytic and cytostatic prperties of an anti-human Fcg RI (CD64) x epidermal growth factor bispecific fusion protein. J Immunol 1997; 158: 872.
- Stockmeyer B, Valerius T, Repp R et al. Preclinical studies with FcgR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997; 57: 696.
- Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV. Spontaneous aggregation as a mechanism for human mono-cyte purification. Cellular Immunology 1986; 101: 312.
- Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27.
- Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517.
- Barrett JM, Kruczynski A, Etievant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoi-somerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 2002; 49: 479.
- Greco WR, Bravo G, Parsons JC. The search for syner-gy: a critical review from a response surface perspective. Pharm Rev 1995; 47: 331.
- Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241.
- Chan OTM, Yang LX. The immunological effects of taxanes Can Immunol Immunother 2000; 49: 181–185.
- Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, de Leij L. The role of apoptosis in bispecific anti-body-mediated T-cell cytotoxicity. Br J Cancer 1996; 73: 721.
- Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor mono-clonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56: 3666.
- Renner C, Held G, Ohnesorge S et al. Role of per-form, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-acti-vated cytotoxic T cells. Can Immunol Immunother 1997; 44: 70.
- Takamuku K, Baba K, Arinaga S, Li J, Mori M, Akiyoshi T. Apoptosis in antibody-dependent monocyte-medi-ated cytotoxicity with monoclonal antibody-dependent mono-cyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Can Immunol Immunother 1996; 43: 220.
- Mabuchi S, Ohmichi M, Kimura A et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277 (36): 33490-500.
- Calabrese EJ, Baldwin LA. Defining hormesis. Human Exp Toxicol 2002; 21: 91.